Glenmark Pharmaceuticals has been granted a patent for antibodies targeting human IL1RAP, with potential binding to monkey and mouse IL1RAP. The antibodies can be used for diagnosing and treating human diseases. GlobalData’s report on Glenmark Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Glenmark Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Glenmark Pharmaceuticals's grant share as of May 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies binding to il1rap for diagnosis and treatment
A recently granted patent (Publication Number: US11970539B2) discloses an anti-IL1RAP antibody with specific characteristics. The antibody comprises a first heavy chain CDR region (CDR-H1), a second heavy chain CDR region (CDR-H2), and a third heavy chain CDR region (CDR-H3), with defined amino acid sequences. Additionally, the antibody includes a light chain variable region with a specific amino acid sequence. The patent also specifies that the antibody binds to human IL1RAP with a particular binding affinity range and can decrease signals stimulated by various interleukins by a significant percentage, as measured by a cell-based blocking assay.
Furthermore, the patent claims cover aspects such as cross-reactivity with IL1RAP polypeptides from cynomolgus monkeys and mice, the antibody's class and isotype, multispecificity, and specific binding to amino acid residues within a specific domain of IL1RAP. The patent also includes a claim for a pharmaceutical composition comprising the anti-IL1RAP antibody and a pharmaceutically acceptable carrier. Overall, the patent provides detailed information on the characteristics and potential applications of the anti-IL1RAP antibody, highlighting its specificity, binding affinity, and potential therapeutic use in pharmaceutical compositions.
To know more about GlobalData’s detailed insights on Glenmark Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
